Comments
Shares of Venus Remedies will remain in focus, as its board of directors will meet on Tuesday to consider issuing fully convertible warrants/ equity shares to promoters on preferential basis. The allotment is, however, subject to approval in the general meeting. It reported a loss of ₹20.66 crore for the quarter ended March 2015 as against a net profit of ₹14.11 crore in the same period previous year. Net sales also declined 28 per cent to ₹98.88 crore (₹142.32 crore).
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.